Pegylated liposomal doxorubicin in salvage chemotherapy for multiple myeloma patients

Current Cancer Therapy Reviews

Volumn 9, Issue 1, 2013, Pages 1-7

  Romano, Alessandra ^a   Uccello, Giuseppina ^a   Spina, Paolo ^a   Cunsolo, Rosario ^b   Vetro, Calogero ^a   Di Raimondo, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Doxorubicin; Multiple myeloma; Relapse; Salvage chemotherapy

Indexed keywords

ANTHRACYCLINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; IDARUBICINE; MITOXANTRONE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; HODGKIN DISEASE; HUMAN; LYMPHOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY;

EID: 84874879777     PISSN: 15733947     EISSN: 18756301     Source Type: Journal    
DOI: 10.2174/1573394711309010001     Document Type: Review

References (53)

1. Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011; 117: 4701-5.
2. Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008; 111: 4039-47.
3. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011, 117:4691-5.
4. Richardson PG, Laubach J, Mitsiades CS, et al. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol 2011.
5. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-98.
6. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17.
7. Cavo M, Attal M, Gertz MA, Giralt S, Ludwig H, Morgan GJ, Anderson KC. The current landscape of multiple myeloma treatment. Leuk Res 2008; 32 (Suppl 1):S1-24.
8. San Miguel JF, Mateos MV, Ocio E, Garcia-Sanz R: Multiple myeloma: treatment evolution. Hematology 2012; 17(Suppl 1):S3-6.
9. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 2004; 351: 1860-73.
10. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892-901.
11. Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs 2011; 71: 2531-58.
12. Plosker GL. Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 2008; 68: 2535-51.
13. Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag 2009; 5: 151-9.
14. Ning YM, He K, Dagher R, et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology (Williston Park) 2007; 21: 1503-8; discussion 1511, 1513, 1516 passim.
15. Voorhees PM, Orlowski RZ. Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma. Clin Lymphoma Myeloma 2007; 7 (Suppl 4): S156-62.
16. Canzoneri JC, Oyelere AK: Interaction of anthracyclines with iron responsive element mRNAs. Nucleic Acids Res 2008; 36: 6825-34.
17. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900-905.
18. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A: Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010; 10: 337.
19. Lokhorst HM, Meuwissen OJ, Bast EJ, Dekker AW. VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989; 71: 25-30.
20. http://www.cancer.gov/cancertopics/druginfo/fda-doxorubicin-HCL-liposome.
21. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/hu man/medicines/000089/human_med_000683.jsp&mid=WC0b01ac 058001d124.
22. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639-47.
23. Takigawa N, Vaziri SA, Grabowski DR, et al. Proteasome inhibition with bortezomib enhances activity of topoisomerase Itargeting drugs by NF-kappaB-independent mechanisms. Anticancer Res 2006; 26: 1869-76.
24. Di Raimondo F, Conticello C. Captivating bortezomib: an active but still mysterious drug. Leuk Res 2010; 34: 411-2.
25. Conticello C, Giuffrida R, Adamo L, et al. NF-βB localization in multiple myeloma plasma cells and mesenchymal cells. Leuk Res 2011; 35: 52-60.
26. Hideshima T, Ikeda H, Chauhan D, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009; 114: 1046-52.
27. Buda G, Ricci D, Huang CC, et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2010; 89: 1133-40.
28. Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 2005; 6: 115-38.
29. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058-65.
30. Biehn SE, Moore DT, Voorhees PM, et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2007; 86: 211-6.
31. Jakubowiak AJ BL, Kendall T, et al. Combination therapy with Velcade, Doxil, and dexamethasone (VDD) for patients with relapsed/refractory multiple myeloma (MM). (Blood 106:378b a ed.; 2005.
32. Jakubowiak AJ, Kendall T, Al-Zoubi A, et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009; 27: 5015-22.
33. Jakubowiak AJ, Griffith KA, Reece DE, et al. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood 2011; 118: 535-43.
34. Sonneveld P, Hajek R, Nagler A, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008; 112: 1529-37.
35. Bladé J, Sonneveld P, San Miguel JF, et al. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 2008; 8: 352-5.
36. Shah J, Bladé J, Sonneveld P, et al. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. Cancer 2011; 117: 3758-62.
37. Bladé J, Sonneveld P, San Miguel JF, et al. Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk 2011; 11: 44-9.
38. Palumbo A, Gay F, Bringhen S, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 2008; 19: 1160-5.
39. Gozzetti A, Fabbri A, Oliva S, et al. Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2010; 10: 68-72.
40. Waterman GN, Yellin O, Swift RA, et al. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma. Ann Hematol 2011; 90: 193-200.
41. Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 2008, 141:814-819.
42. Buda G, Orciuolo E, Galimberti S, Pelosini M, Petrini M. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients. Ann Hematol 2011; 90: 1115-6.
43. Reske T, Fulciniti M, Munshi NC. Mechanism of action of immunomodulatory agents in multiple myeloma. Med Oncol 2010; 27 (Suppl 1): S7-13.
44. Chanan-Khan AA, Lee K. Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience. Clin Lymphoma Myeloma 2007; 7 (Suppl 4): S163-9.
45. Hussein MA. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. Oncologist 2003; 8 (Suppl 3): 39-45.
46. Hussein MA, Anderson KC. Role of liposomal anthracyclines in the treatment of multiple myeloma. Semin Oncol 2004; 31: 147-60.
47. Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009; 113: 4137-43.
48. Caravita T, Siniscalchi A, Tendas A, et al. Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience. Ann Hematol 2011; 90: 115-6.
49. Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006; 17: 1766-71.
50. Chanan-Khan A, Miller KC. Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. Leuk Lymphoma 2005; 46: 1103-4.
51. Hütter G, Szélenyi H, Schmittel A, Siehl JM, Thiel E, Keilholz U. Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone). Hematol Oncol 2007; 25: 132-9.
52. A. Romano AC, A. Gorgone, L. Schinocca, et al. Efficacy of the combination therapy of liposomal adryamicin, bortezomib, cyclophosphamide and dexamethasone (abcd) in relapsed/refractory multiple myeloma patients. In EHA Annual Conference; Amsterdam. Hematologica 2012.
53. C Giannakoulas DP, J Befani, T Zisaki, A Bouronikou, G Vassilopoulos, T Matsouka. High response rate in newly diagnosed multiple myeloma patients treated with a combination of cyclophosphamide, liposomal doxorubicin, dexamethasone and bortezomib. (16th of the European Hematology Association L, UK, June 9-11, 2011 ed.: Hematologica 2011.